Vantis Vascular

Coming – December 11

Reducing PCI Procedure Times From 3 Hours To 30 Minutes

Date and Time

December 11

–

12:00 PM ET / 9:00 AM PT

Details will be provided upon RSVP approval

About this Event

Vantis Vascular is a physician-founded medical device company developing breakthrough tools that enable interventional cardiologists to safely, effectively, and efficiently treat the most challenging coronary vascular cases.

Each year, millions of patients require percutaneous coronary interventions (PCI), yet in as many as 20% of the cases, physicians have to resort to more invasive procedures like open-heart surgery or forgo treatment altogether.

Vantis Vascular’s CrossFAST™ Integrated Microcatheter Advanced Delivery System, dramatically improves deliverability and control in these high-risk cases. Early preclinical data demonstrates compelling advantages:
  • 2x greater intubation depth
  • 100% deliverability
  • Procedure time reduction from as much as 3 hours to 30 minutes
  • Reduced patient radiation exposure in the Cath lab

Already in commercial use, CrossFAST is receiving rave reviews from cardiologists including statements like: “Your device is clutch! The device saved me. There’s nothing else that would go down that artery.”

Vantis is led by an experienced team of operators and renowned interventional cardiologists and is supported by advisors from leading institutions such as Mass General, Emory, and Scripps.

Please join our online event with Jason Turner, CEO of Vantis Vascular, to hear how they are poised to become a category-defining leader in advanced vascular intervention.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.